A Phase 1 safety and feasibility of AGT-103
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
At a glance
- Drugs AGT-103 (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man
- 12 Oct 2017 According to an American Gene Technologies International media release, the company expects to file its IND with the Food and Drug Administration during the first quarter of 2018 and interim safety and early efficacy data are expected by the third quarter of 2018.
- 12 Apr 2017 According to an American Gene Technologies International media release, company intends to initiate this trial later in 2017.
- 03 Apr 2017 New trial record